Clik here to view.
BioBlast Pharma Announces Cabaletta Phase 3 Study In OPMD Patients - Quick Facts
BioBlast Pharma Announces Cabaletta Phase 3 Study In OPMD Patients - Quick Facts
View ArticleClik here to view.
AERI Rockets On FDA Feedback, ADXS On The Job, ITCI To Report Trial Data In Q3
AERI Rockets On FDA Feedback, ADXS On The Job, ITCI To Report Trial Data In Q3
View ArticleClik here to view.
AERI Rockets On FDA Feedback, ADXS On The Job, ITCI To Report Trial Data In Q3
AERI Rockets On FDA Feedback, ADXS On The Job, ITCI To Report Trial Data In Q3
View ArticleClik here to view.
AERI Rockets On FDA Feedback, ADXS On The Job, APRI To Report Trial Data In Q3
AERI Rockets On FDA Feedback, ADXS On The Job, APRI To Report Trial Data In Q3
View ArticleClik here to view.
European Commission Grants Orphan Drug Status For Cabaletta To Treat OPMD
European Commission Grants Orphan Drug Status For Cabaletta To Treat OPMD
View ArticleClik here to view.
AQXP Fails To Lead, Concordia To Get Better Visibility, EXAC Gets FDA Nod
AQXP Fails To Lead, Concordia To Get Better Visibility, EXAC Gets FDA Nod
View ArticleClik here to view.
BioBlast Pharma Gets Orphan Drug Designation From EU For Cabaletta - Quick Facts
BioBlast Pharma Gets Orphan Drug Designation From EU For Cabaletta - Quick Facts
View ArticleClik here to view.
EBIO To Report Phase III Data In May, EYPT Catches Eyes, SIEN Gets FDA Nod
EBIO To Report Phase III Data In May, EYPT Catches Eyes, SIEN Gets FDA Nod
View ArticleClik here to view.
Mark Your Calendar For May 15, DXR Makes A Comeback, OBSV Abuzz, CVM On Watch
Mark Your Calendar For May 15, DXR Makes A Comeback, OBSV Abuzz, CVM On Watch
View ArticleClik here to view.
FDA Snubs PTIE Again, OVID's STARS Fail To Shine, HAIR Keeps Falling
FDA Snubs PTIE Again, OVID's STARS Fail To Shine, HAIR Keeps Falling
View ArticleClik here to view.
XBIO To Report Phase 2 Data This Year, VNRX Abuzz, ATRS To Face FDA In Sep
XBIO To Report Phase 2 Data This Year, VNRX Abuzz, ATRS To Face FDA In Sep
View ArticleClik here to view.
PTI Jumps Over 400% On CF Data, GRTS, YMAB March Ahead, NVS Acquires ECYT
PTI Jumps Over 400% On CF Data, GRTS, YMAB March Ahead, NVS Acquires ECYT
View Article
